Interstitial lung diseases (ILDs) represent a diverse group of more than 200 lung disorders characterized by inflammation and fibrosis of the lung interstitium. This article aims to provide healthcare professionals with a comprehensive understanding of ILDs, their diagnosis, and treatment options.
ILDs can be idiopathic or secondary to systemic diseases, occupational and environmental exposures, or drug toxicity. The pathogenesis typically involves damage to the lung interstitium, leading to an aberrant repair response, inflammation, fibrosis, and ultimately, loss of lung function.
Patients with ILDs often present with non-specific symptoms such as dyspnea, cough, and fatigue. High-resolution computed tomography (HRCT) is the cornerstone of ILD diagnosis. Pulmonary function tests, bronchoalveolar lavage, and lung biopsy may also be used for diagnosis and to assess disease severity.
Management strategies for ILDs are multifaceted and depend on the underlying cause. In idiopathic cases, treatment is largely supportive, including supplemental oxygen and pulmonary rehabilitation. Pharmacological therapies, such as corticosteroids and immunosuppressants, are used in cases of inflammatory ILDs. Antifibrotic agents are increasingly used in managing fibrotic ILDs. Lung transplantation remains a last resort for patients with advanced disease.
Given the complexity of ILDs, a multidisciplinary approach is essential for optimal patient management. This approach includes pulmonologists, radiologists, pathologists, rheumatologists, and patient support groups. This collaborative approach ensures comprehensive patient care and improves outcomes.
Interstitial lung diseases are complex disorders requiring a thorough understanding for effective management. As healthcare professionals, staying updated on the latest diagnostic and therapeutic advances is crucial to provide the best possible care for patients with ILDs.
1.
Mosunetuzumab in Follicular Lymphoma: Durable Responses and Manageable Safety
2.
As EGFR internalization is decreased, BUB1 controls EGFR signaling.
3.
Getting Lung Cancer Screening Staff Involved Improved Tobacco Cessation
4.
Low Income, Education Tied to Depression in Older Adults
5.
In Higher-Risk MDS, CMML, All-Oral Therapy Has Promise.
1.
Bridging Disciplines: Medical Oncology vs Surgical Oncology in the Era of Multidisciplinary Cancer Care
2.
Next-Gen CAR Cell Therapies in Oncology: Frontiers in Solid Tumors & Hematologic Malignancies
3.
Next-Generation Sequencing in Oncology: Unlocking the Future of Precision Medicine
4.
Unlocking the Key to Treating Lymphoma: New Innovations in Cancer Research
5.
Personalizing Cancer Care: Microbiome Advances, Challenges, and Future Directions
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part VI
2.
Targeting Oncologic Drivers: A New Approach to Lung Cancer Treatment
3.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part IV
4.
Managing CNS diseases at the point of diagnosis in ALK + NSCLC
5.
Navigating the Complexities of Ph Negative ALL - Part XV
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation